Novartis Cancer Drug Wins Priority Review

Feb. 27, 2017

Novartis announced that its lung cancer drug, Zykadia, has secured priority review status from the U.S. FDA for treating patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase-positive.

Zykadia was first approved in April 2014 as a second-line treatment for patients with metastatic ALK-positive NSCLC who were previously treated with Pfizer's Xalkori.

Novartis has claimed, based on the results of a late-stage study, that its drug is twice as effective as chemotherapy in slowing the growth of non-small cell lung cancer.

Read the Investopedia coverage